560 results about "Recombinant antigen" patented technology

The present invention relates to immunological adjuvants comprised of the N-formyl methionyl peptide fMLP. FMLP, when used as an adjuvant in accordance with the present invention, provides for an immune response to suboptimal doses of recombinant antigens.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore

The invention provides a detection kit of IgM/IgG antibodies of novel coronavirus (SARS-CoV-2), and relates to the technical field of biology. According to the detection kit of IgM/IgG antibodies of novel coronavirus (SARS-CoV-2), the IgM/IgG antibodies of novel coronavirus (SARS-CoV-2) are detected through adoption of a colloidal gold capture method, a colloidal gold indirect method and a colloidal gold double antigen sandwich method, wherein adopted antigens are highly active recombinant antigens which are obtained through fusion expression of N protein fragments and S protein dominant epitope fragments, and colloidal gold is labeled indirectly, so that steric hindrance is reduced, and the activity, reaction consistency and accuracy of the antigens are increased. Since a sample pad is pretreated, the interference of complex components in a blood sample to a reaction can be reduced greatly, the detection kit has no requirements for instruments during detection, simple and flexible operation, direct and manual interpretation of results and a short test time, the results can be interpreted in only 15 minutes, and the test results are accurate.

There is provided by this invention a specific and sensitive diagnostic method for rapid detection of lymphatic filariasis. The method employs a combination of SXP/SXP-recombinant antigen, mouse monoclonal anti-human IgG4 antibody conjugated to a detection reagent and the technique of immunochromatography.

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.

The invention relates to a kit and a method for quantitatively detecting urine microalbumin through time-resolved fluorescence. The kit comprises a time-resolved fluorescence test paper card, sample diluent and a DS card containing a calibration curve, wherein the time-resolved fluorescence test paper card comprises a detection test paper strip which consists of a bottom liner, and a sample pad, a nitrocellulose membrane and absorbent paper which are pasted on the bottom liner; the nitrocellulose membrane is successively provided with a microsphere line, a detection line and a quality control line; the microsphere line consists of time-resolved fluorescence microspheres marked with human seroalbumin monoclonal antibodies; the detection line is coated with human seroalbumin recombinant antigens; the quality control line is coated with goat anti-mouse IgG. The kit provided by the invention can accurately and quantitatively detect the content of microalbumin in human urine; markers are used for connecting the microspheres with antibodies through covalent bonds; and the marked products are stable. The kit has the characteristics of wide detection range (2 to 300mg/ml), high sensitivity (the detection limit is 2300mg/ml), high accuracy, fast and easy detection and the like.

The invention discloses a pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and application thereof and belongs to the field of biological vaccines. The pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen adopts a strategy of an antigenized antibody, after main antigen epitopes of a plurality of strains of pig foot-and-mouth disease virus O-type are connected in series reasonably, the plurality of strains of pig foot-and-mouth disease virus O-type are coupled with a pig intravenous gamma globulin (IgG) heavy chain constant region to construct the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen, and after ration through a Bio-Rad protein ration kit, the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and recombination foot-and-mouth disease virus 3D protein are matched to prepare the vaccines. Animal immunity testing results show that the vaccines can stimulate an organism to generate high-titer protective antibodies when the vaccines are used independently or matched with the recombination foot-and-mouth disease virus 3D protein to be used, an antibody level is higher than a national standard, and good application prospects are achieved.

The invention discloses a test strip for detecting HIV antibodies in spittle and a preparation method thereof. The test strip comprises a sample pad, a fiberglass film, a nitrocellulose film and absorbent paper, wherein the fiberglass film is tightly connected with one end of the sample pad and contains colloidal gold particle markers; the nitrocellulose film is tightly connected with the other end of the fiberglass film; the absorbent paper is tightly connected with the other end of the nitrocellulose film; the sample pad, the fiberglass film, the nitrocellulose film and the absorbent paper are all arranged on a base plate; the nitrocellulose film comprises a detection area coated with HIV recombinant antigens and a control area coated with goat anti rabbit antibodies; and the colloidal gold particle marker comprises a colloidal gold particle-avidin-biotin-antihuman IgG antibody composite micro-signal amplification system, and colloidal gold marking rabbie IgG antibodies. Due to the adoption of the avidin-biotin micro-signal amplification system, the test strip amplifies signals of the target antibodies, improves detection sensitivity and avoids false negative or detection omission caused by too weak signals.

The invention discloses a recombinant antigenic protein for diagnosing echinococcosis granulosus (having an amino acid sequence represented by SEQIDNo.1). In addition, the invention also discloses the preparation method of the recombinant antigenic protein, which comprises: amplifying an EgEPC1 gene by using RT-PCR; cloning the EgEPC1 gene in a pGEM-T vector; connecting the EgEPC1 gene with an expression vector PET28a(+) to form a recombinant plasmid PET28a-EgEPC1; transforming the recombinant plasmid PET28a-EgEPC1 to Escherichia coli BL21(DE3) and expressing the recombinant protein through IPTG induction; and identifying a purified recombinant antigen by using SDS-PAGE and Western blotting. In addition, the invention also discloses the diagnosis use of the recombinant antigenic protein. Experiments show that the recombinant antigenic protein of the invention has the advantages of high sensibility and specificity for the diagnosis of echinococcosis granulosus, and has a promising application prospect in the diagnosis of the echinococcosis granulosus.

The invention discloses a dengue virus IgG/IgM antibody detection test strip, kit and preparation method thereof, and relates to the technical field of dengue virus detection. The dengue virus IgG/IgMantibody detection test strip of the invention comprises a sample pad, an immune combination pad, a nitrocellulose membrane and absorbent paper, wherein the sample pad is sequentially stuck to the bottom of polyvinyl chloride; the immune combination pad is coated with dengue virus recombinant antigen marked by colloidal gold and chicken IgY polyclonal antibody; the nitrocellulose membrane is coated with dengue virus anti-human IgM antibody, a detection line of IgG antibody and a quality control line of anti-chicken IgY polyclonal antibody. The test strip can detect whether dengue virus IgG/IgM antibody exists in a sample to be detected through a method for detecting a marker. The test strip and the detection card comprising the test strip can be used as supplement for antigen detection onthe early acute infection of the dengue virus, covering the middle and later stages of the disease course and reducing the risk of missed detection.

The present invention provides an infectious bursal disease virus (IBDV) subunit antigen-containing vaccine composition, which contains an immune amount of recombinant VP2 protein and an adjuvant. According to the present invention, with the subunit gene engineering vaccine composition, the infectious bursal disease can be effectively prevented and controlled; and with the purification technology adopted by the recombinant antigen protein, the endotoxin content in the vaccine composition is significantly reduced, the side reaction of the chicken individuals is significantly reduced, and the safety of the vaccine is substantially increased.

The invention relates to the technical field of biology and discloses a mycoplasma pneumoniae (MP) recombinant antigen, and a preparation method and an application of the mycoplasma pneumoniae recombinant antigen. An amino acid sequence of the mycoplasma pneumonia recombinant antigen is shown as SEQ ID No: 1. According to the antigen, a section of amino acid is taken as connecting oligopeptide, and an MP specific antigen P1 proteantigen dominant epitope and a P30 antigen dominant epitope form a recombinant protein. Tests prove that the recombinant protein has higher specificity and sensitivity in comparison with the existing MP antigen, and can be used for preparing MP antibody testing products.

The invention discloses a composite IgY antibody for resisting COVID-19 and SARS. The antibody is prepared by the following method: constructing a recombinant antigen of SARS-CoV-2 and SARS-CoV; preparing an immune preparation with the recombinant antigen to immunize egg-producing birds, and obtaining the specific composite IgY antibody from the immunized eggs. A spray prepared by the antibody canbe used for broad-spectrum killing of SARS-CoV-2 and SARS-CoV, and is suitable for spraying on nasal cavity, oral cavity, skin and other parts. The antibody preparation has a specific virus neutralizing effect, can effectively control infection sources, protect susceptible people, disinfect and protect first-line medical staff and prevent spread of SARS-CoV-2.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

The invention relates to the technical field of biology, and particularly provides a novel coronavirus recombinant antigen coating solution, a pretreatment method, application and a product. The coronavirus recombinant antigen coating solution is composed of a PBS buffer solution, acidic amino acid, BSA, mannitol, trehalose, Proclin300 and water, the stability of the novel coronavirus recombinantantigen in the detection reagent can be effectively improved through mutual coordination and cooperation of all the components, and the sensitivity and specificity of the novel coronavirus antibody detection reagent are effectively improved. Besides, the inventor treats the novel coronavirus recombinant antigen by utilizing DNA hydrolase, randomly decomposes a host DNA fragment in the novel coronavirus recombinant antigen to generate oligonucleotide, eliminates the interference of the DNA fragment on a later antigen detection antibody, and has a remarkable result.

The invention relates to a diagnostic reagent kit for testing the hepatitis c virus (HCV) and the preparation and test method, which is to add the HCV recombinant antigen used for peridium into the buffer solution, blend it, move into the luminous microplate, make incubation for 18 hours under 4DEG.C, wash the luminous microplate, add into the confining liquid, leave the liquid after incubation and fully dry the luminous microplate to complete the preparation of the pre-peridium luminous microplate; combine the anti-human IgG used for marking and the horse radish peroxidase by improving the sodium periodate to complete the preparation of the enzyme marker; prepare the chemical luminous substrate solution A with luminal, Tween20 and luminous intensifier and prepare the chemical luminous substrate solution B with the hydrogen peroxide. The reagent kit also comprises the sample diluent and concentrated scrub solution. The negative corresponds to the normal human serum while the positive corresponds to the people with serum of pooled serum with HCV antibody. The reagent kit provided in the invention has much higher detection sensitivity than the ELISA, which is safe and reliable, easy to operate with low cost, and without any expensive full-automatic chemical luminous measuring apparatus required.

The invention relates to a treponema pallidum (TP) antibody test kit based on the flow microspheric carrier technology and a preparation method and detection method thereof, belonging to the technical field of immunoassay medical diagnosis. The preparation method comprises the following steps: using TP recombinant antigen to coat heavy polymer microsphere, using bovine serum albumin to seal empty binding site, preparing specific TP probe-heavy polymer microsphere; performing coculture with a sample to be tested to capture TP antibody, washing and centrifuging to remove the unbound TP antibody, then adding fluorescently-labeled anti-human IgG or IgM antibody; and using a flow cytometry to detect the fluorescence intensity of the microsphere, and performing qualitative or quantitative analysis to the tested antibody. The method has the advantages of high sensitivity and specificity and good stability and can be used to perform microanalysis or multivalent analysis to the sample.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.

The invention relates to a novel detection reagent card for coronavirus antibody detection. The reagent card comprises a sample pad, a quantum pad, a nitrocellulose membrane, absorbent paper and a lining plate, the quantum pad is coated with a quantum dot microsphere labeled anti-human IgM antibody or IgG antibody, a detection line arranged on the nitrocellulose membrane is coated with an SARS-COV2 recombinant antigen, and a quality control line is coated with goat anti-mouse IgG. According to the detection reagent card for detecting the novel coronavirus (SARS-COV2) IgM antibody or IgG antibody provided by the invention, a result can be rapidly and accurately obtained, and auxiliary diagnosis is provided for clinical COVID-19.

The invention relates to a method for preparing a porcine circovirus type 2 colloidal gold antibody fast test strip. In the method, a porcine circovirus type 2 ORF2 protein is expressed by utilizing genetic engineering, and the test strip is prepared by the principle of enzyme-linked immunoassay and membrane chromatography to fast test antibodies in the blood or serum of pigs. The test strip can be widely used for clinically testing porcine circovirus diseases, has no cross reaction with other viruses, and obtains test results 98.63 percent and 95.83 percent consistent with those obtained by the two methods of the ELISA and neutralization test. Compared with the ELISA, a recombinant antigen immune colloidal gold has the remarkable advantages of high security, no need of culturing the viruses per se, the avoidance of virus spread caused by the operation of the viruses, large-batch preparation, simple process, low production cost, stable and homogeneous antigen components, simple, convenient and labor-saving operation, no apparatus, high detection result specificity, high repeatability, the short time of 15 minutes for the whole test, simple, convenient, fast and accurate operation, high sensitivity, intuition and easy result judgment.

The invention relates to a preparation method for an African swine fever virus (ASFV) antibody detection colloidal gold immunochromatography test paper strip, belonging to the field of bioengineering and animal epidemic disease diagnosis. The preparation method comprises the following steps of: expressing an ASFV recombinant antigen p54, purifying, preparing an antibody, preparing a colloidal gold immunochromatography test paper strip, and detecting the sensitivity and specificity of the ASFV antibody. Compared with the other conventional serological methods, the colloidal gold immunochromatography test paper strip prepared by the method has the advantages of convenience, quickness, sensitivity, specificity and the like, can be used for obtaining a definite diagnosis result within 5 minutes and directly detecting a suspicious swine serum (or anticoagulation) virus antibody, and is particularly suitable for field ASFV serological diagnosis, epidemiological survey and swine international trade quarantine and inspection.

The invention provides a recombination antigen composition, a vaccine and a carrier and a method for preparing the antigen composition. A recombination helicobacter pylori antigen which comprises a helicobacter pylori antigen, the fusion proteins of a cholera toxin CT-A2 subunit and cholera toxin CT-B proteins is optimized. The compatibility of the CT-A2 and the CT-B proteins is used, a chimeric structure of CT-A2-5CT-B is formed, and accordingly an antigen with higher titer is formed through the helicobacter pylori antigen and the fusion proteins of the cholera toxin CT-A2 subunit. Meanwhile, the effect that the CT-B enhances immunization is used, and the effect that the antigen immunogenicity of the recombination antigen composition is enhanced is achieved. In addition, the chimeric protein constituted by the recombination antigen stimulates a mucous membrane to generate secreting type IgA immunization.